Business description: Zoetis Inc.

Zoetis Inc. specializes in developing, manufacturing and marketing of animal health products. Net sales break down by activity as follows:

- companion animal (67.8%): cats and dogs (95.5% of net sales) and horses (4.5%);

- livestock (31.3%): cattle (52.8% of sales), poultry (18.2%), swine (17.8%), fish (8.4%) and other (2.8%);

- other (0.9%).

Net sales break down by family of products into parasiticides (23.3%), vaccines (19.7%), dermatological products (17.9%), anti-infectives (11.9%), pain relievers (9.2%), diagnostic products (4.2%), medicated feed additives (3.2%) and other (10.6%).

At the end of 2024, the group has 22 production sites worldwide.

The United States accounts for 54.8% of net sales.

Number of employees: 13,800

Sales by Activity: Zoetis Inc.

Fiscal Period: December20202021202220232024

United States (U.S.)

355.7Cr 404.2Cr 431.3Cr 455.5Cr 507.4Cr

International

303.5Cr 365.2Cr 368.1Cr 391.1Cr 410.2Cr

Unallocated Contract Manufacturing & Human Health

8.3Cr 8.2Cr 8.6Cr 7.8Cr 8Cr
See all business segments

Geographical breakdown of sales: Zoetis Inc.

Fiscal Period: December20202021202220232024

United States (U.S.)

355.7Cr 404.2Cr 431.3Cr 455.5Cr 507.4Cr

Other Emerging Markets

66Cr 78Cr 76Cr 78Cr 86Cr

Other Developed Markets

39Cr 47Cr 47Cr 51Cr 56Cr

Brazil

26Cr 31Cr 33Cr 39Cr 41Cr

Australia

21Cr 26Cr 29Cr 32Cr 32Cr

United Kingdom

18Cr 23Cr 24Cr 28Cr 31Cr

Canada

21Cr 23Cr 24Cr 26Cr 28Cr

China

27Cr 36Cr 38Cr 32Cr 27Cr

Germany

16Cr 18Cr 18Cr 20Cr 22Cr

Mexico

12Cr 13Cr 14Cr 16Cr 17Cr

France

12Cr 13Cr 13Cr 14Cr 16Cr

Japan

18Cr 19Cr 17Cr 16Cr 15Cr

Spain

11Cr 13Cr 12Cr 12Cr 13Cr

Italy

9Cr 12Cr 11Cr 12Cr 13Cr

Chile

10Cr 14Cr 14Cr 14Cr 12Cr

Unallocated

8.3Cr 8.2Cr 8.6Cr 7.8Cr 8Cr
See all geographic segments

Executive Committee: Zoetis Inc.

Manager TitleAgeSince
Chief Executive Officer 53 01/01/2020
Director of Finance/CFO 53 01/06/2021
Chief Operating Officer 52 01/08/2024
Chief Tech/Sci/R&D Officer - 21/03/2024
Chief Tech/Sci/R&D Officer 47 01/03/2023
See ZOETIS INC. governance

Composition of the Board of Directors: Zoetis Inc.

Director TitleAgeSince
Chairman 67 01/07/2012
Director/Board Member 67 01/01/2013
Chairman 72 26/06/2013
Director/Board Member 72 01/06/2013
Director/Board Member 74 01/08/2013
Director/Board Member 70 04/03/2014
Director/Board Member 64 01/05/2015
Director/Board Member 53 02/10/2019
Director/Board Member 63 08/12/2020
Director/Board Member 56 25/07/2022
Composition of the Board of Directors

Shareholders: Zoetis Inc.

NameEquities%Valuation
Western Asset Management Company DTVM Ltda.
0.006211 %
4,44,985 0.006211 % 5 M R$
BRAM - Bradesco Asset Management SA DTVM
0.000204 %
14,600 0.000204 % 153 920 R$
NameEquities%Valuation
Vanguard Fiduciary Trust Co.
9.28 %
4,15,56,164 9.28 % 7 008 M R$
BlackRock Advisors LLC
6.196 %
2,77,43,573 6.196 % 4 678 M R$
4.421 %
1,97,96,791 4.421 % 3 338 M R$
State Farm Investment Management Corp.
3.549 %
1,58,92,903 3.549 % 2 680 M R$
Eaton Vance Management
2.846 %
1,27,46,041 2.846 % 2 149 M R$
List of ZOETIS INC. shareholders

Company details: Zoetis Inc.

Zoetis, Inc.

10 Sylvan Way

07054, Parsippany

+973 822 7000

http://www.zoetis.com
address Zoetis Inc.(Z1TS34)

Group companies: Zoetis Inc.

NameCategory and Sector
Zoetis Treasury Center BV
Biotechnology
Zoetis Biopharmaceutical Co. Ltd.
Pharmaceuticals: Major
Zoetis Singapore Pte Ltd.
See all subsidiaries

Veterinary Drugs

Change 5d. change 1-year change 3-years change Capi.($)
-0.32%+6.07%-20.33%-34.20% 708.71Cr
-0.10%+0.42%-2.82%-3.21% 360.16Cr
-0.78%-4.23%-10.20%-6.07% 307.27Cr
-2.08%-0.61%+20.91%-20.38% 237.72Cr
+1.76%-18.81%+45.21%+28.52% 135.33Cr
-2.87%-5.14%+5.40%-23.71% 110.22Cr
+0.43%0.00%-15.11%-41.44% 100.08Cr
-0.41%+0.96%-28.14%-35.25% 100Cr
+1.23%+2.51%+37.74%+34.56% 99Cr
Average -0.36%+0.18%+3.63%-11.24% 239.78Cr
Weighted average by Cap. -0.45%+1.56%-3.46%-16.27%
See all sector performances
Trading Rating
Investor Rating
ESG MSCI
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
19
Last Close Price
166.33USD
Average target price
195.37USD
Spread / Average Target
+17.46%
Consensus

Quarterly revenue - Rate of surprise